KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Net Income towards Common Stockholders rose 11907.22% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 10323.88%. This contributed to the annual value of $226.5 million for FY2024, which is 46949.87% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Net Income towards Common Stockholders stood at $71.8 million, which was up 11907.22% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $143.7 million in Q4 2024 and a low of -$113.1 million during Q1 2022
  • Over the past 5 years, Acadia Pharmaceuticals' median Net Income towards Common Stockholders value was -$14.5 million (recorded in 2021), while the average stood at -$5.3 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Net Income towards Common Stockholders crashed by 13948.56% in 2023, and later soared by 289721.72% in 2024.
  • Acadia Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$43.1 million in 2021, then rose by 3.29% to -$41.7 million in 2022, then soared by 209.89% to $45.8 million in 2023, then soared by 213.87% to $143.7 million in 2024, then crashed by 50.06% to $71.8 million in 2025.
  • Its last three reported values are $71.8 million in Q3 2025, $26.7 million for Q2 2025, and $19.0 million during Q1 2025.